Nazan Günel

Nazan Günel

Auto-generated profile, based on publicly available information

Nazan Günel

Department of Medical Oncology, Gazi University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VAVolkan Aslan
Volkan Aslan
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
AÖAhmet Özet
Ahmet Özet
AÜAytuğ Üner
Aytuğ Üner
NGNazan Günel
Nazan Günel
NÖNuriye Özdemir
Nuriye Özdemir
Introduction: Resistance to immune checkpoint inhibitors (ICI) is a significant issue in metastatic renal cell carcinoma (mRCC), as it is in the majority of cancer types. An important deficiency in immunooncology today is the lack of a predictive factor to identify this patient group. Myeloid-derived suppressor cells (MDSC) are a type of cell that contributes to immunotherapy resistance by inhibiting T cell activity. While it accumulates in the tumor microenvironment and blood, it can also accumulate in lymphoid organs such as the spleen and cause splenomegaly. Therefore we aimed to evaluate the effect of increase in splenic volume, which can be considered as an indirect indicator of increased MDSC cells, on survival outcomes in mRCC patients. Methods: We analyzed 45 patients with mRCC who received nivolumab as a second-line or subsequent therapy. Splenic volume was analyzed from baseline imaging before starting nivolumab and from control imaging performed within the first 6 months of treatment initiation. Additionally, we analyzed how patients’ body mass index (BMI), IMDC risk score, ECOG performance status, nephrectomy status, neutrophil-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR) and sites of metastasis. Results: Median splenic volume change was 10% (ranging from − 22% to + 117%) during follow-up. Change in splenic volume was found to be associated with overall survival (OS) and progression-free survival (PFS) (p = 0.025, 0.04). The median PFS in patients with increased splenic volume was 5 months, while it was 17 months in patients without increased splenic volume. (HR 2.1, 95% CI (1–4), p = 0.04). The median OS in patients with increased splenic volume was 9 months, while it was 35 months in patients without increased splenic volume (HR 2.7, 95% CI (1.1–6.2), p = 0.025). In four patients with decreased splenic volume, neither PFS nor OS could reach the median value. Log-rank p value in respectively (0.015, 0.035), The group in which an increase in volume was accompanied by a high NLR had the shortest survival rate. Basal splenic volume was analyzed separately. However, neither PFS nor OS differed significantly. Conclusion: Our findings suggest that the change in splenic volume throughout immunotherapy regimens may be utilized to predict PFS and OS in mRCC patients undergoing treatment.

20 September 2022 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
VAVolkan Aslan
Volkan Aslan
AKAtiye Cenay Karabörk Kılıç
Atiye Cenay Karabörk Kılıç
OSOsman Sutcuoglu
Osman Sutcuoglu
EEEmrah Eraslan
Emrah Eraslan
ABAHMET BAYRAK
AHMET BAYRAK
OYOzan Yazıcı
Ozan Yazıcı

26 January 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
KYKadriye Bir Yücel
Kadriye Bir Yücel
ZOZeynep Irem Ozay
Zeynep Irem Ozay
OSOsman Sutcuoglu
Osman Sutcuoglu
OYOzan Yazıcı
Ozan Yazıcı
AÜAytug Üner
Aytug Üner
NÖNuriye Özdemir
Nuriye Özdemir

1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
GTGozde Tahtaci
Gozde Tahtaci
NGNazan Günel
Nazan Günel
ASAysu Sadi̇oĞlu
Aysu Sadi̇oĞlu
NANalan Akyurek
Nalan Akyurek
OBOğulcan Boz
Oğulcan Boz
AÜAytuğ Üner
Aytuğ Üner
Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman's correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. Results: The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15-2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56-13.02) (p = 0.215), respectively). Conclusion: High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.

14 August 2023 in Journal of Chemotherapy
Verified
Journal Article
Closed access
KYKadriye Bir Yücel
Kadriye Bir Yücel
AKAtiye Cenay Karabörk Kilic
Atiye Cenay Karabörk Kilic
OSOsman Sutcuoglu
Osman Sutcuoglu
OYOzan Yazıcı
Ozan Yazıcı
KKKoray Kilic
Koray Kilic
NÖNuriye Özdemir
Nuriye Özdemir
The aim of our study was to evaluate the association between increased splenic volume (SV) and liver fibrosis indices in colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Patients who received adjuvant oxaliplatin-based regimens with the diagnosis of stage II and III colon cancer were evaluated. Splenic volume measurements, liver function tests, platelet count, and non-invasive liver fibrosis indices [NAFLD fibrosis score (NFS), AST to platelet ratio (APRI), and Fibrosis-4 (FIB-4)] were measured before and after treatment. A 30% increase in SV after chemotherapy compared to baseline was considered increased SV. The rate of increase in SV was 57.7% in the whole group. An increase in SV was shown at a higher rate in patients treated with capecitabine and oxaliplatin (CAPOX) than those treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) (66.3% vs. 36.8%, p = 0.002). Furthermore, the CAPOX regimen (OR: 2.831, 95% CI: 1.125-7.121; p = 0.027), and higher post-treatment FIB-4 score (OR: 3.779; 95% CI:1.537- 9.294, p = 0.004) were determined as independent risk factors for the increased SV. Our study revealed that increased SV had a significant association with higher FIB-4 score in patients treated with oxaliplatin-based chemotherapy.

1 December 2021 in Immunotherapy
Verified
Journal Article
Closed access
OSOsman Sutcuoglu
Osman Sutcuoglu
AIAysegul Ilhan
Aysegul Ilhan
STSeher Yıldız Tacar
Seher Yıldız Tacar
DGDeniz Can Guven
Deniz Can Guven
GUGokhan Ucar
Gokhan Ucar
OYOzan Yazıcı
Ozan Yazıcı
Background: The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. Methods: The data of 1432 patients treated with immu...